Inclusion Criteria:  Severe symptomatic aortic valve stenosis (AVA ≤1 cm² or 0.6 cm²/m²) with indication for transcatheter aortic valve implantation according to heart team consensus Perimeter-derived native aortic valve annulus diameter measuring 21-27 mm Heart team consensus that the patient is anatomically suitable for both device types Suitability for transfemoral vascular access Written informed consent  Exclusion Criteria:  Life expectancy <12 months due to comorbidities Native aortic valve annulus <21 mm and >27 mm Bicuspid aortic valve Cardiogenic shock or hemodynamic instability Active endocarditis Contraindications for transfemoral access Active peptic ulcer or upper gastro-intestinal bleeding <2 weeks Hypersensitivity or contraindication to aspirin, heparin or clopidogrel Contraindication for a specific mode of anesthesia as judged by the cardiac anesthesia representative of the Heart Team Clear patient-specific clinical or anatomic reasons to prefer one form of anesthesia or valve type over the other Active infection requiring antibiotic treatment Age <18 years Participation in another trial